OBJECTIVES: Reconstruction techniques after a mastectomy have improved greatly in recent years, with much more natural results. Even so, a third of women choose not to have reconstruction. They turn to breast forms medical devices (MDBF). MDBF are reimbursed from Health insurance funds, but for MDBF with higher functional properties, there is a presence of higher patient co-payment. METHODS: The target of the work was to analyse the data from paid databases of Slovak authority National Center for Health Information that collects the outputs of provided health care. The data were focused on totally or partly reimbursed medical devices (MD) from public health insurance funds RESULTS: Referring to the National Center for Health Information, in the observed period, the share of MDBF on total consumption of MD stagnated (MDBF/MD=0.0039%; MDBF/MD=0.0038%; ΔMDBF/MD=-0.0001%). The total quantitative consumption MDBF increased (Δ=458pcs/14.16%; max=4 101pcs; min=3 235pcs; AVG=3 693pcs; Mean=3 685pcs; SD=333). The share of MDBF on total reimbursement of MD stagnated (MDBF/MD=0.14%; MDBF/MD=0.12%; ΔMDBF/MD=-0.02%). The total reimbursement in the observed period increased (Δ=12 174€/6.93%; max=187 736€; min=175 562€; AVG=179 050€; Mean=179 554€; SD=5 651). The share of MDBF on the patient supplements of MD stagnated (MDBF/MD=0.27%; MDBF/MD=0.23%; ΔMDBF/MD=-0.04%). The total patient supplements increased (Δ=3 700€/43.36%; max=12 234€; min=8 534€; AVG=11 637€; Mean=12 234€; SD=1 835).  CONCLUSIONS: Development of MDBF costs is almost stable. MDBF has a higher patient co-payment. This fact is due to the current legislation when more patients choose breast forms of character higher functional properties that increase the comfort after mastectomy.